Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE

The purpose of this randomized, placebo-controlled phase 2b study is to prospectively evaluate AD04's potential as a disease-modifying drug in AD. By evaluating the safety, pharmacodynamics, and efficacy of AD04 in early AD patients, we aim to deliver a comprehensive and robust data set that furthers our understanding of the effects of AD04 in AD pathology.

NCT Number	NCT07107074
Lead Sponsor	ADvantage Therapeutics
Conditions	Alzheimer Disease, Early Onset
Enrollment	122 participants
Start Date	2023-11-08
Primary Completion	2026-12 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2025-08-06